Cannabinoid receptor 2–Serotonin receptor 1A heteromer (CB2–5-HT1A heteromer)

The Cannabinoid receptor 2–Serotonin receptor 1A (CB2–5-HT1A) heteromer is a G protein-coupled receptor complex formed by the direct physical interaction of CB2 and 5-HT1A receptors [1, 2]. This heteromer is characterized by unique signaling properties, including cross-antagonism, where an antagonist for one receptor can block the activation of the other within the complex [1, 3]. It plays a significant role in neuroprotection, particularly in the context of neonatal hypoxic-ischemic brain damage (NHIBD), where its expression is markedly upregulated in response to injury [1, 4]. Cannabidiol (CBD) is a prominent modulator of this heteromer, and its therapeutic benefits in brain injury models are largely mediated through this interaction, which helps normalize receptor expression and signaling [2, 3]. Additionally, the heteromer is being explored as a target for non-psychoactive treatments for depression and anxiety using dual agonists like the CBD derivative 2o [8]. Understanding the specific pharmacology of this complex allows for the development of more precise therapies that avoid the side effects associated with individual receptor activation [1, 10].

Other names

CB2-5-HT1A complexCB2R-5-HT1AR heteromerCannabinoid CB2 and Serotonin 5-HT1A heteroreceptor complexCB2-5-HT1A-Het

The mechanism involves allosteric modulation and functional cross-talk between the Cannabinoid receptor 2 (CB2) and Serotonin receptor 1A (5-HT1A) within the heteromeric complex [1, 2]. This interaction leads to altered Gi/o protein-mediated signaling pathways, characterized by phenomena such as cross-antagonism, where the blockade of one receptor inhibits the signaling of the other [1, 3]. Drugs like Cannabidiol (CBD) modulate this complex to exert neuroprotective effects, particularly by reducing the aberrant upregulation of the heteromer during hypoxic-ischemic events [2, 4].